BR112022010677A2 - Uso de reboxetina para tratar transtornos do sistema nervoso - Google Patents

Uso de reboxetina para tratar transtornos do sistema nervoso

Info

Publication number
BR112022010677A2
BR112022010677A2 BR112022010677A BR112022010677A BR112022010677A2 BR 112022010677 A2 BR112022010677 A2 BR 112022010677A2 BR 112022010677 A BR112022010677 A BR 112022010677A BR 112022010677 A BR112022010677 A BR 112022010677A BR 112022010677 A2 BR112022010677 A2 BR 112022010677A2
Authority
BR
Brazil
Prior art keywords
reboxetine
nervous system
system disorders
esreboxetine
cataplexy
Prior art date
Application number
BR112022010677A
Other languages
English (en)
Portuguese (pt)
Inventor
Tabuteau Herriot
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/740,329 external-priority patent/US20200147093A1/en
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Priority claimed from PCT/US2020/062560 external-priority patent/WO2021113163A1/en
Publication of BR112022010677A2 publication Critical patent/BR112022010677A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112022010677A 2019-12-03 2020-11-30 Uso de reboxetina para tratar transtornos do sistema nervoso BR112022010677A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962943077P 2019-12-03 2019-12-03
US201962946295P 2019-12-10 2019-12-10
US16/740,329 US20200147093A1 (en) 2018-10-15 2020-01-10 Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US16/740,411 US20200147096A1 (en) 2018-10-15 2020-01-11 Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US16/740,410 US20200147095A1 (en) 2018-10-15 2020-01-11 Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US16/740,409 US11351175B2 (en) 2018-10-15 2020-01-11 Use of reboxetine to treat narcolepsy
PCT/US2020/062560 WO2021113163A1 (en) 2019-12-03 2020-11-30 Use of reboxetine to treat nervous system disorders

Publications (1)

Publication Number Publication Date
BR112022010677A2 true BR112022010677A2 (pt) 2022-08-16

Family

ID=81851750

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010677A BR112022010677A2 (pt) 2019-12-03 2020-11-30 Uso de reboxetina para tratar transtornos do sistema nervoso

Country Status (12)

Country Link
EP (1) EP4069244A4 (ko)
JP (1) JP2023504685A (ko)
KR (1) KR20220108122A (ko)
CN (1) CN114746097A (ko)
AU (1) AU2020395082A1 (ko)
BR (1) BR112022010677A2 (ko)
CA (1) CA3163505A1 (ko)
CO (1) CO2022007507A2 (ko)
CR (1) CR20220247A (ko)
IL (1) IL293536A (ko)
MX (1) MX2022006630A (ko)
PE (1) PE20230181A1 (ko)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL197985B1 (pl) * 1999-07-01 2008-05-30 Upjohn Co Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku
PT1459750E (pt) * 1999-07-01 2005-08-31 Pharmacia & Upjohn Co Llc (s,s)- reboxetina para tratar a fibromialgia ou outras perturbacoes somatoformes
CA2686723A1 (en) * 2007-05-07 2008-11-13 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
TWI684450B (zh) * 2013-03-13 2020-02-11 南韓商愛思開生物製藥股份有限公司 猝倒症之治療

Also Published As

Publication number Publication date
PE20230181A1 (es) 2023-02-01
EP4069244A1 (en) 2022-10-12
AU2020395082A1 (en) 2022-06-09
CR20220247A (es) 2022-08-18
EP4069244A4 (en) 2023-12-20
CN114746097A (zh) 2022-07-12
KR20220108122A (ko) 2022-08-02
IL293536A (en) 2022-08-01
JP2023504685A (ja) 2023-02-06
CO2022007507A2 (es) 2022-06-21
MX2022006630A (es) 2022-06-24
CA3163505A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
BR112016027773A2 (pt) peptídeo célula-penetrante, polinucleotídeo, proteína recombinante célula penetrante de toxina botulínica, vetor de expressão recombinante, bactéria, composição farmacêutica, composição cosmética e método para produzir uma proteína recombinante célula-penetrante de toxina botulínica
BR112018068565A2 (pt) combinações de inibidores de lsd1 para uso no tratamento de tumores sólidos
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
CO6561786A2 (es) Terapia combinada para el tratamiento del cancer y ensayos de diagnostico relacionados
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer
BR112018076639A2 (pt) quimioterapias de combinação
BR112015025424A2 (pt) tratamento de câncer usando terapias de combinação de coenzima q10
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
BR112019022280A2 (pt) tratamento de cânceres de her2 positivo
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112012030641B8 (pt) Usos e composições para terapia farmacêutica oral
BR112019003136A2 (pt) forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo
BR112022020643A2 (pt) Método de tratamento de esteato-hepatite não alcoólica
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
BR112023006024A2 (pt) Terapias de imuno-oncologia com conjugados de il-2
BR112022010702A2 (pt) Macrociclos para uso no tratamento de doenças
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
BR112018017233A2 (pt) uso de i. butyriciproducens e/ou e. hallii, e, composição
BR112022007721A2 (pt) Método para o tratamento da demência
CO2022014499A2 (es) Moduladores de nlrp3
BRPI0602397C1 (pt) composições farmacêuticas para o tratamento das doenças gordurosas do fìgado, obesidade e demais doenças associadas à sìndrome metabólica e métodos de tratamento utilizando-se as referidas composições
BR112019002945A2 (pt) terapia de combinação para o tratamento de câncer pancreático
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase